These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31396957)

  • 1. Oxidative phosphorylation as a potential therapeutic target for cancer therapy.
    Sica V; Bravo-San Pedro JM; Stoll G; Kroemer G
    Int J Cancer; 2020 Jan; 146(1):10-17. PubMed ID: 31396957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling.
    Lee JS; Lee H; Jang H; Woo SM; Park JB; Lee SH; Kang JH; Kim HY; Song J; Kim SY
    Cells; 2020 Sep; 9(9):. PubMed ID: 32883024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
    Levitzki A; Klein S
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11579-11586. PubMed ID: 31076554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?
    López-Lázaro M
    Anticancer Agents Med Chem; 2008 Apr; 8(3):305-12. PubMed ID: 18393789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OXPHOS inhibitors, metabolism and targeted therapies in cancer.
    Cadassou O; Jordheim LP
    Biochem Pharmacol; 2023 May; 211():115531. PubMed ID: 37019188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer.
    De Rosa V; Iommelli F; Monti M; Fonti R; Votta G; Stoppelli MP; Del Vecchio S
    Clin Cancer Res; 2015 Nov; 21(22):5110-20. PubMed ID: 26216352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the low inhibitory specificity of oxamate, aminooxyacetate and dichloroacetate on cancer energy metabolism.
    Moreno-Sánchez R; Marín-Hernández Á; Del Mazo-Monsalvo I; Saavedra E; Rodríguez-Enríquez S
    Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt A):3221-3236. PubMed ID: 27538376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents.
    Yadav N; Kumar S; Marlowe T; Chaudhary AK; Kumar R; Wang J; O'Malley J; Boland PM; Jayanthi S; Kumar TK; Yadava N; Chandra D
    Cell Death Dis; 2015 Nov; 6(11):e1969. PubMed ID: 26539916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative phosphorylation as a target to arrest malignant neoplasias.
    Rodríguez-Enríquez S; Gallardo-Pérez JC; Marín-Hernández A; Aguilar-Ponce JL; Mandujano-Tinoco EA; Meneses A; Moreno-Sánchez R
    Curr Med Chem; 2011; 18(21):3156-67. PubMed ID: 21671858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative Phosphorylation as an Emerging Target in Cancer Therapy.
    Ashton TM; McKenna WG; Kunz-Schughart LA; Higgins GS
    Clin Cancer Res; 2018 Jun; 24(11):2482-2490. PubMed ID: 29420223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-kinase inhibitors, AURKs and cancer.
    Cicenas J; Cicenas E
    Med Oncol; 2016 May; 33(5):43. PubMed ID: 27038473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 and glucose metabolism: an orchestra to be directed in cancer therapy.
    Gomes AS; Ramos H; Soares J; Saraiva L
    Pharmacol Res; 2018 May; 131():75-86. PubMed ID: 29580896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer.
    Jin N; Bi A; Lan X; Xu J; Wang X; Liu Y; Wang T; Tang S; Zeng H; Chen Z; Tan M; Ai J; Xie H; Zhang T; Liu D; Huang R; Song Y; Leung EL; Yao X; Ding J; Geng M; Lin SH; Huang M
    Nat Commun; 2019 Jun; 10(1):2701. PubMed ID: 31221965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.
    Kim M; Baek M; Kim DJ
    Curr Pharm Des; 2017 Nov; 23(29):4226-4246. PubMed ID: 28625132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism.
    Pathania D; Millard M; Neamati N
    Adv Drug Deliv Rev; 2009 Nov; 61(14):1250-75. PubMed ID: 19716393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
    Tibes R; Trent J; Kurzrock R
    Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
    Xu Y; Xue D; Bankhead A; Neamati N
    J Med Chem; 2020 Dec; 63(23):14276-14307. PubMed ID: 33103432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits.
    Denise C; Paoli P; Calvani M; Taddei ML; Giannoni E; Kopetz S; Kazmi SM; Pia MM; Pettazzoni P; Sacco E; Caselli A; Vanoni M; Landriscina M; Cirri P; Chiarugi P
    Oncotarget; 2015 Dec; 6(39):41706-21. PubMed ID: 26527315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P
    Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.